Literature DB >> 31694564

Comparison of different endoscopic resection techniques for submucosal tumors originating from muscularis propria at the esophagogastric junction.

Hong-Wei Xu1, Qi Zhao1, Shu-Xia Yu1, Ying Jiang1, Jing-Hua Hao1, Bin Li2.   

Abstract

BACKGROUND: To compare the outcomes of submucosal tunneling endoscopic resection (STER) and submucosal excavation (ESE) for the treatment of submucosal tumors (SMTs) arising from the muscularis propria (MP) at the esophagogastric junction (EGJ).
METHODS: A retrospective analysis of patients with SMTs at EGJ who underwent STER and ESE from October 2011 to October 2017 was performed. The outcomes evaluated were operation time, complete resection rate, adverse events, and tumor recurrence.
RESULTS: Ninety patients were included in this study. Complete resection rates in the STER group were higher than those of the ESE group (100 vs. 92%, p < 0.05). For tumors ≤15 mm, both techniques achieved 100% complete resection rate; but for tumors > 15 mm, complete resection rate was higher in the STER group than the ESE group (100% vs. 77.8%, p < 0.05). Subgroup analyses revealed that the operation time of STER for in cardiac-gastric group was longer than that for ESE (145.14 ± 42.43 min vs. 70.32 ± 39.84 min, p <  0.05). The air leakage symptoms were more frequent in STER group (90.9% vs. 50.0%, p < 0.05). No tumor recurrence occurred in both the STER and ESE groups.
CONCLUSIONS: For SMTs ≤15 mm, both STER and ESE have similar satisfactory therapeutic outcomes. However, in the cardiac-gastric subgroup, STER had a longer operative time compared to the ESE procedure. For SMTs > 15 mm, STER is the preferred choice due to its higher complete resection rate.

Entities:  

Keywords:  Endoscopic submucosal excavation; Esophagogastric junction; Muscularis propria; Submucosal tumor; Submucosal tunneling endoscopic resection

Mesh:

Year:  2019        PMID: 31694564      PMCID: PMC6833169          DOI: 10.1186/s12876-019-1099-5

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


Background

Submucosal tumors (SMTs) at the esophagogastric junction (EGJ) are defined as the submucosal tumors located partially or fully within 1 cm proximal and 2 cm distal to the esophagogastric junction (squamo-columnar junction) [1]. SMTs are usually covered with normal gastrointestinal mucosa, and most patients have no specific clinical manifestations [2]. Moreover, some mesenchymal neoplasms, including gastrointestinal stromal tumors (GISTs), have malignant potential [3, 4]. Thus, surgical resection is often suggested, especially for high-risk tumors or patients who are greatly worried about their long-term prognosis. Previously, surgical wedge resection was the preferred option for SMTs [5]. With advancements in technologies and techniques, therapeutic endoscopic procedures have evolved as alternative approaches for the excision of SMTs [6-9]. It has been reported that gastrointestinal SMTs, especially those originating from the muscularis mucosa ventriculi and submucosa, can be successfully removed by endoscopic submucosal dissection (ESD), endoscopic submucosal excavation (ESE), and endoscopic full-thickness resection (EFR) [10]. The ESE technique involves making a tiny incision of the mucous membrane above the lesion and dissection the tumor directly. Nevertheless, for SMTs arising from muscularis propria (MP) layer, particularly those growing outside the cavity and densely adhered to the serosal layer, complete resection is difficult and risky [11]. Currently, submucosal tunneling endoscopic resection (STER) is well developed for the treatment of these SMTs [12]. Inspired by these good outcomes, we began using STER for endoscopic resection of SMTs arising from the MP layer of the EGJ. The advantage of this tunneling technique is that it maintains the integrity of the surrounding mucosa of the lesion. With the tunneling technique, the lesion is not required to be in a horizontal plane with the mucous cut which may maintain the integrity of the surrounding mucosa. The direct ESE is also a good option for resection of the tumor due to its shorter operative time. Till now, very few studies on the excision of SMTs originating from the MP layer of the EGJ have been reported [13]. The purpose of this study was to compare the efficacy and safety of STER and ESE for resection of SMTs.

Methods

Patients

This was a retrospective study involving consecutive patients admitted to Department of Gastroenterology, Shandong Provincial Hospital affiliated to Shandong University between October 2011 and October 2017. This study was approved by the Institutional Review Board of Shandong Provincial Hospital affiliated to Shandong University. Written informed consent was obtained from each participant before surgery. Patients who met the following criteria were included: (1) SMTs located partially or fully at the EGJ with origin from the MP layer as confirmed by endoscopic ultrasonography (EUS); (2) the maximum diameter of the tumor less than 3.0 cm. The exclusion criteria were as follows: (1) lesions originating from the mucosal/submucosal layer; (2) patients unfit for general anesthesia; (3) predominant extraluminal growth was shown by EUS or computed tomography (CT).

Grouping

The patients were classified into three groups based on the location of the lesions: esophagocardiac, cardiac, and cardiac-gastric groups (Fig. 1). In the esophagocardiac group, the tumor was partially located within the EGJ area and its distal margin failed to reach the squamo-columnar junction. The tumor located within the anatomic EGJ and straddled the squamo-columnar junction were considered as cardiac group. The tumor partially locating below the anatomic EGJ and its proximal margin failed to reach the squamo-columnar junction were included into cardiac-gastric group.
Fig. 1

Grouping of the patients with submucosal tumors. The patients were classified into the cardiac group if the tumor’s center was within the anatomic EGJ and straddled the squamo-columnar junction. The patients were classified into the esophagocardiac group if the tumor was partially located above the anatomic EGJ and its distal edge failed to reach the squamo-columnar junction. The patients were classified into the gastrocardiac group if the tumor was partially located below the anatomic EGJ and its proximal edge failed to reach the squamo-columnar junction. EGJ, esophagogastric junction, was defined as the area within 1 cm above and 2 cm below the squamo-columnar junction

Grouping of the patients with submucosal tumors. The patients were classified into the cardiac group if the tumor’s center was within the anatomic EGJ and straddled the squamo-columnar junction. The patients were classified into the esophagocardiac group if the tumor was partially located above the anatomic EGJ and its distal edge failed to reach the squamo-columnar junction. The patients were classified into the gastrocardiac group if the tumor was partially located below the anatomic EGJ and its proximal edge failed to reach the squamo-columnar junction. EGJ, esophagogastric junction, was defined as the area within 1 cm above and 2 cm below the squamo-columnar junction

ESE procedure

ESE was performed under general anesthesia. Antibiotics were given intravenously 0.5 h before the procedure. The operation was conducted using a single and/or dual-channel endoscope (Olympus). The operative steps were as follows: Marking of the tumor location (Fig. 2a): Argon or coagulation was used to mark the oral and anal end of the target lesion.
Fig. 2

Procedure of endoscopic submucosal excavation. a: Marking of the submucosal tumor with argon knife; b: Submucosal injection with fluid mixture; c: Incision of the covering mucosa; d: Identification of the submucosal tumor; e, f: Peeling off the lesions; g: The wound after resection; h: Closure of the mucosal incision by clips

Submucosal injection (Fig. 2b ,c): A solution prepared using saline, indigo carmine and epinephrine was injected into submucosa to elevate the lesion so as to facilitate separation of the covering mucosal and submucosal layer from the lesion. Exposure of the lesion (Fig. 2d): The covering mucosa was incised longitudinally using a dual or hook knife over the tumor along the marked site, followed by separation of the submucosa to expose the tumor using endoscopic submucosal dissection. Peeling of the lesion (Fig. 2e, f): After dissecting the submucosal and muscular tissue around the tumor capsule, the lesion was peeled with IT2 or Hook knife. Wound treatment (Fig. 2g, h): Hot biopsy forceps was used for achieving hemostasis during the operation. The small blood vessels were burned by argon. If the residual cavity was deep, the mucosal incision was approximated by clips to avoid delayed hemorrhage or perforation. Procedure of endoscopic submucosal excavation. a: Marking of the submucosal tumor with argon knife; b: Submucosal injection with fluid mixture; c: Incision of the covering mucosa; d: Identification of the submucosal tumor; e, f: Peeling off the lesions; g: The wound after resection; h: Closure of the mucosal incision by clips

STER procedure

The complete procedure of STER has been described previously by Xu et al. [6] In this study, the procedure was modified as below: Localization of the tumor (Fig. 3a): Argon or dual knife was used to mark the tumor (Fig. 3b).
Fig. 3

Procedure of submucosal tunneling endoscopic resection. a: The submucosal tumor; b: Marking of the tumor with argon knife; c: Creation of the submucosal tunnel; d: Visualization of the submucosal tumor; e: Dissection of the tumor from the muscular layer within the submucosal tunnel; f: The lesion; g: The wound after resection; h: Closure of the mucosal incision with clips

Construction of a submucosal tunnel (Fig. 3c): After injecting a fluid cushion about 5 cm proximal to the SMT, a 2-cm longitudinal mucosal entry point was made by using a dual or hook knife on the esophageal mucosa. A submucosal longitudinal tunnel was then created with dual knife. The tunnel terminated at about 1–2 cm distal to the tumor to provide good endoscopic view of the SMT and sufficient space for dissection. Exposure of the tumor (Fig. 3d): The level of difficulty of exposing the SMT depends on its location. Local injection of methylene blue in the original SMT before endoscopic tunneling was performed to facilitate identification of the tumor. Resect the SMT. Separation of the MP layer was performed by using an IT2 or Hook knife (Fig. 3e, f). complete resection of the tumor including its capsule was performed. Damage to the esophageal adventitia or gastric serosa was avoided. Hemostasis (Fig. 3g): After tumor resection, hot biopsy forceps were used to control hemorrhage and exposed small arteries in order to avoid late onset bleeding [14]. Closure of the mucosal incision (Fig. 3h). Procedure of submucosal tunneling endoscopic resection. a: The submucosal tumor; b: Marking of the tumor with argon knife; c: Creation of the submucosal tunnel; d: Visualization of the submucosal tumor; e: Dissection of the tumor from the muscular layer within the submucosal tunnel; f: The lesion; g: The wound after resection; h: Closure of the mucosal incision with clips

Postoperative management and follow up

Postoperative management included monitoring for chest pain, dyspnea, and other discomforts [13-15]. Possible complications included gas leakage into the surrounding tissue or lacuna, hemorrhage, perforation, infection, and pain. Once perforation, subcutaneous emphysema, or pneumothorax occurred, antibiotics were administered for as long as 48 h after surgery. The patient’s body temperature was closely monitored, and blood culture testing was performed. When patients complained of severe pain, they were monitored for signs of infection or perforation. The main outcomes included the complete resection rate, the tumor recurrence rate, and the rate of complications including subcutaneous emphysema, pneumothorax, pneumoperitoneum. Follow-up esophagogastroscopy and EUS were performed at an interval of 3 months during the first year after surgery, and every 6 months during the following 2–5 years to evaluate wound healing and timely identification of any residual or recurrent tumor. The CT scan was used in cases of GIST to detect distant metastasis.

Statistical analysis

SPSS 16.0 software (SPSS, Chicago, IL, USA) was used for all statistical analyses. The Student t-test, Chi square test, and Fisher’s exact test were used for the comparisons between the groups. Data were presented as mean ± standard deviation. A difference was considered significant when p <  0.05.

Results

Clinical characteristics

There were 90 patients having 94 SMTs included in this study. The details of the patients and SMTs in both the STER and ESE groups are listed in Table 1. There was no significant difference in the age between the two groups. The male:female ratio was higher in STER group than in ESE group. In the STER group, one patient had three SMTs and two patients had two SMTs. The mean resected lesion size was 22.05 ± 7.67 mm. For six patients, the size of the lesions was < 1 cm (For details, see the Additional file 1: Tables S1 and S2). But due to the fear of malignancy, these six patients had severe anxiety and insisted for endoscopic resection. The main pathology type was leiomyoma (70.45%).
Table 1

Detailed information about the patients and SMTs of STER and ESE group

Detailed informationSTERESEP value
Characteristics of patients
 Number4050/
 Average age (years)52.05 ± 10.1553.06 ± 8.840.143, NS a
 Gender ratio (M/F)22/1816/340.028
Characteristics of tumor
 Number4450/
 Size (mm)22.05 ± 7.66715.32 ± 7.7700.000
 Location (%)
  Esophagus cardiac14 (31.82)6 (12)/
  Cardiac14 (31.82)6 (12)/
  Cardiac-gastric fundus16 (36.36)38 (76)0.000
 Pathological type (%)
  Leiomyoma31 (70.45)34 (68.00)/
  GIST10 (22.73)14 (28)/
  Schwannoma2 (4.55)2 (4)/
  Lipoma1 (2.27)00.699, NS a

M/F Male/Female, GIST gastrointestinal stromal tumor, ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance

Detailed information about the patients and SMTs of STER and ESE group M/F Male/Female, GIST gastrointestinal stromal tumor, ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance In ESE group, the mean resected lesion size was 15.32 ± 7.77 mm. The main pathology type was leiomyoma (68.00%). Histological examination showed that the majority of the lesions below the cardia to be GISTs, whereas those above the squamo-columnar junction were leiomyomas.

Clinical outcomes

The characteristics and treatment outcomes of STER and ESE are summarized in Table 2 respectively. The overall complete resection rate in STER was significantly higher than in ESE (ESE: 92%, STER 100%, p <  0.05). In four cases, the lesions were too large and deep to perform en bloc resection. In these cases, a part of the lesion was resected for pathological examination which confirmed them to be GIST. Two of the four cases had delayed bleeding and underwent surgical excision. The remaining two patients refused further treatment. The mean time required to resect SMTs was shorter with ESE compared to STER (69.40 ± 39.68 min vs. 104.90 ± 49.59 min, p <  0.05).
Table 2

Comparison of clinical outcomes between STER and ESE

Clinical outcomesSTERESEP value
Number of lesions4450
Complete resection (%)10092<  0.05
Mean procedure time, min (range)104.9000 ± 49.59105 (37.00–185.00)69.4000 ± 39.68344 (29.00–160.00)<  0.05
Histology diagnosis (%)
 Leiomyoma31 (70.45)34 (68.00)
  Spindle cell type tumors (Immunohistochemical staining showed leiomyoma)3 (6.82)0
 GIST10 (22.72)14 (28.00)
  Very low malignant4 (9.09)0
  Low malignant6 (13.64)8 (16.00)
  Intermediate malignant06 (12.00)
 Schwannoma2 (4.54)2 (4.00)
 Lipoma1 (2.27)0
Complications (%)228< 0.05
 Subcutaneous emphysema12 (54.55)2 (25.00)
 Mediastinal emphysema00
 Pneumothorax6 (27.27)2 (25.00)
 Pneumoperitoneum2 (9.09)0
 Hemorrhage02 (25.00)
 Perforation00
 Nasal bleeding2 (9.09)0
 Delayed bleeding00
 Fever02 (25.00)
Median follow-up period, month (range)17.5250 ± 14.3169 (6.00–48.00)11.9600 ± 6.5371 (3.00–24.00)
Tumor recurrence00NSa

GIST gastrointestinal stromal tumor, ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance

Comparison of clinical outcomes between STER and ESE GIST gastrointestinal stromal tumor, ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance Mediastinal emphysema/infection was not observed in either of the groups. In ESE group, pneumothorax occurred in two patients. These cases were treated by closed thoracic drainage for three days. In two cases, delayed hemorrhage occurred one day after complete resection. The bleeding was controlled by endoscopic spraying of Monsel’s Solution (Monsel’s salt, a ferrous sulfite solution) over the bleeding point. Two cases developed fever two days after the operation which was managed by three days of antibiotics therapy (Table 2). In the STER group, subcutaneous emphysema and pneumothorax developed in 12 and 6 patients respectively. The incidence of subcutaneous emphysema with STER was significantly higher than ESE (Table 2).

Subgroup analysis based on the tumor location

In the STER group, the complication rate in the esophago-cardiac group was remarkably lower than that in the cardiac and the cardiac-gastric groups. The mean operation time in the esophago-cardiac and cardiac groups was significantly shorter in contrast with that of the cardiac-gastric group (Table 3).
Table 3

Subgroup analysis based on the tumor location of STER and ESE group

STER groupESE groupP value
Complications rate (%)
 Esophagus-cardia0/14 (0)2/6 (33.33)
 Cardia6/12 (50)0/6 (0)
 Cardiac-gastric fundus8/14 (57.14)4/38 (10.53)
  P10.0030.121, NSa
  P20.0010.130, NSa
  P30.716, NSa0.405, NSa
Operating time (min)
 Esophagus-cardia83.43 ± 23.1440883.00 ± 54.75NSa
 Cardia83.00 ± 52.7946350.00 ± 2.68NSa
 Cardiac-gastric fundus145.1429 ± 42.4315970.3158 ± 39.84< 0.05
  P10.980, NSa0.200, NSa
  P20.0000.49, NSa
  P30.0030.004

STER submucosal tunneling endoscopic resection, ESE endoscopic submucosal excavation; aNo Significance; P1, the comparison of esophagus-cardia and cardia; P2, the comparison of esophagus-cardia and cardia-gastric; P3, the comparison of cardia-gastric and cardia

Subgroup analysis based on the tumor location of STER and ESE group STER submucosal tunneling endoscopic resection, ESE endoscopic submucosal excavation; aNo Significance; P1, the comparison of esophagus-cardia and cardia; P2, the comparison of esophagus-cardia and cardia-gastric; P3, the comparison of cardia-gastric and cardia In the ESE group, the complication rate in the esophago-cardiac group was higher than that in the cardiac and the cardiac-gastric groups. The operation time in the cardiac-gastric group was significantly longer than the cardiac group (p = 0.004, Table 3). As shown in the Table, the mean operating time of STER and ESE were similar in the esophago-cardiac and cardiac groups. But in the cardiac-gastric group, ESE had a shorter mean operating time.

Subgroup analysis based on tumor size

We divided the patients with tumor size > 15 mm and ≤ 15 mm into separate groups (Table 4). For tumors ≤15 mm, the complete resection rate with both ESE and STER was 100% without perforation. The mean operating time was longer with STER than ESE. For tumors > 15 mm, STER group had a higher complete resection rate but also a higher complication rate than ESE group. Both groups had similar operating time.
Table 4

Subgroup analysis on clinical outcomes of ESE and STER

STERESEP value
Lesion size ≤15 mm
 Number1332
 Mean tumor size (mm)11.85 ± 2.4110.19 ± 2.250.033
 Operation time (min)102.85 ± 55.9955.63 ± 35.220.032
 Complete resection rate (%)13/13 (100)32/32 (100)1.000, NSa
 Perforation rate (%)00
 Complications rate (%)10/11 (90.9) b4/32 (12.5)< 0.05
  Subcutaneous emphysema60
  Pneumoperitoneum20
  Pneumothorax20
  Bleeding02
  Fever02
Lesion size > 15 mm
 Number3118
 Mean tumor size (mm)26.32 ± 4.2424.44 ± 5.2040.18, NSa
 Operation time (min)112.58 ± 47.7593.89 ± 35.850.21, NSa
 Complete resection rate (%)31/31 (100)14/18 (77.8)< 0.05
 Perforation rate (%)00
 Complications rate (%)12/29 (41.4)c4/18 (22.2)< 0.05
  Subcutaneous emphysema62
  Pneumoperitoneum00
  Pneumothorax42
  Bleeding20
  Fever00

ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance; bIn one case, there were three lesions (≤ 15 mm), therefore the case number with lesion size ≤15 mm was 11, while the lesion number was 13; c In two cases, each had two lesions (> 15 mm), therefore the case number with lesion size > 15 mm was 29

Subgroup analysis on clinical outcomes of ESE and STER ESE endoscopic submucosal excavation, STER submucosal tunneling endoscopic resection; aNo Significance; bIn one case, there were three lesions (≤ 15 mm), therefore the case number with lesion size ≤15 mm was 11, while the lesion number was 13; c In two cases, each had two lesions (> 15 mm), therefore the case number with lesion size > 15 mm was 29

Follow up outcomes

Mucosal cicatrization without tumor recurrence were visible in all patients who underwent complete excision on follow-up endoscopy at 3, 6, 12, and 24 months after the procedure of STER or ESE.

Discussion

Gastrointestinal SMTs are mostly leiomyomas and GISTs which can be differentiated based only on histopathological examination [16]. Currently, the best diagnostic method is endoscopic ultrasound-guided fine-needle aspiration [17]. The treatment option is controversial if the SMT is suspected to be a GIST. According to the 2017 National Comprehensive Cancer Network guidelines, surgical resection is recommended for the GISTs with symptoms, those > 2 cm in diameter, or < 2 cm but with suspicious EUS features such as irregular border, cystic areas, ulceration, echogenic foci, and heterogeneity. While the 2012 European Society for Medical Oncology guidelines recommend all histologically confirmed GIST to be resected [16], long-term follow-up is suggested as even low-risk GIST can recur as long as 10 years later if you do not choose surgical resection [18]. As a minimally invasive approach, endoscopic resection is a good alternative for upper gastrointestinal SMTs with the advantages being mild surgical trauma, rapid recovery, and fewer adverse effects on digestive tract function. Additionally, endoscopic resection can remove the tumor completely and provide specimens for pathological examination [19, 20]. Endoscopic resection includes ESE, EFR, and STER. STER, first proposed by Chinese scholars, is based on the principles of endoscopic tunneling technique mainly useful in resecting esophageal and gastric cardiac SMTs and is an innovative application of ESD. Compared with other endoscopic approaches, STER has some prominent advantages. First, the integrity of the mucosa and submucosa can be restored by closing the mucosal incision with several clips. Second, the 5-cm-long submucosal tunnel acts as a safeguard against post-procedure leak and prevents the development of digestive tract fistulae or pleural/abdominal infection. Third, due to good visualization of the MP layer in the submucosal tunnel, precise hemostasis can be easily achieved [6]. However, the tunneling technique itself has its drawbacks, since relatively straight and relatively fixed gastrointestinal lumen are required for the construction of tunnel, and not all parts of the digestive tract are suitable for the submucosal tunnel creation. In addition, STER requires advanced training and a long operating time while ESE is a technical extension of ESD, a commonly used procedure to excise early-stage carcinoma. For lesions involving the entire thickness of the muscle, EFR is one of the endoscopic therapeutic options. For small lesions, after EFR the size of defect is small and can be easily closed by endoscopy. But for larger lesions, it is difficult to seal the perforation by endoscopy especially those wound close to the gastroesophageal junction and the cardia. Hence, we seldom use EFR method for larger lesions located near the gastroesophageal junction. In such cases we use ESE or STER. The advantage of ESE is that ESE can be used for most of the gastrointestinal SMTs and the operation time is relatively short compared to STER. Furthermore, based on the available literature, STER does not have considerable advantages over ESE either in the complete resection rate or in the incidence of adverse events [19-25]. Due to stenosis, sharp corners, special anatomical structure, small endoscopic space and technical difficulties, SMTs arising from muscularis propria are difficult to treat with endoscopy. Endoscopic resection technique based on ESD (ESE, STER) is safe and effective for the treatment of SMTs which arise from EGJ muscularis propria [26-29]. However, few studies have focused on the application and the comparison between endoscopic therapies such as STER and ESE in SMTs originating from the MP layers at the EGJ. Also, there is no comparative study focusing on the outcomes of different subtypes of SMTs at EGJ. Our team developed ESE, STER technology based on the ESD. With SMTs at EGJ, the complete resection rate was higher in STER than that in ESE for the large tumor (≥ 1.5 cm) due to physiological cardiac stenosis. In addition, the mean operating time in STER group was longer than that in ESE. Especially in cardiac-gastric subgroup, STER operating time was significantly longer than the ESE. Because of the special location, for the SMTs located near the greater curvature of the cardia, we needed more time to create the submucosal tunnel as the tunnel mucosa was liable to be damaged and it is more difficult to find the lesion. However, we created the submucosal tunnel safely in most cases by careful performance. The incidence of postoperative complications was higher in STER. The main complications were the subcutaneous emphysema, pneumothorax and pneumoperitoneum due to leakage of the gas into interstitial space during the procedure. But all these complications could be easily managed because of the use of carbon dioxide gas. For the tumor closely related with the serosa, in order to ensure the complete removal of the tumor, the entry of the gas into the interstitial space was inevitable. In all complete resection cases, no postoperative gastrointestinal fistula occurred. As the tumor size increases, the endoscopic resection time, the difficulty of the operation, risk of perforation, and delayed bleeding risk also increases [30]. For tumors less than 15 mm in diameter, both ESE and STER had high complete resection rate. Operation time was significantly longer in STER, especially in cardiac-gastric group. There are some limitations of our research. This was a retrospective study in which selection bias is inevitable. Our initial experience with STER included a limited sample size, which constituted another weakness. Additionally, the 2-year follow-up was not enough to determine long-term results.

Conclusions

In conclusion, for SMTs ≤15 mm, both ESE and STER had similar efficacy, but the operative time was shorter for ESE. For SMTs > 15 mm, particularly irregularly shaped lesions, crossing the cardia, ESE may not resect the SMT completely and may be technically difficult to close the mucosal incision. Hence, STER is recommended as the preferred method of treatment due to its higher complete resection rate, although the operation time for STER is longer and finding the lesion in the fundus of the stomach though the submucosal tunnel is more difficult. Additional file 1: Table S1. Clinicopathological characteristics and treatment outcomes of submucosal tumors of the esophagogastric junction originating from the muscularis propria layer treated by STER. Table S2. Clinicopathological characteristics and treatment outcomes of submucosal tumors of the esophagogastric junction originating from the muscularis propria layer treated by ESE.
  30 in total

Review 1.  Surveillance strategies for gastrointestinal stromal tumors.

Authors:  Travis E Grotz; John H Donohue
Journal:  J Surg Oncol       Date:  2011-12       Impact factor: 3.454

2.  Endoscopic submucosal resection with double ligation technique for treatment of small rectal carcinoid tumors.

Authors:  J H Moon; J H Kim; C H Park; J O Jung; W G Shin; J P Kim; K O Kim; T Hahn; K-S Yoo; S H Park; C K Park
Journal:  Endoscopy       Date:  2006-05       Impact factor: 10.093

3.  Preliminary experience of endoscopic submucosal tunnel dissection for upper gastrointestinal submucosal tumors.

Authors:  W Gong; Y Xiong; F Zhi; S Liu; A Wang; B Jiang
Journal:  Endoscopy       Date:  2012-02-21       Impact factor: 10.093

4.  Endoscopic resection for the treatment of gastric subepithelial tumors originated from the muscularis propria layer.

Authors:  Jae Chul Hwang; Jin Hong Kim; Jang Hee Kim; Sung Jae Shin; Jae Youn Cheong; Kee Myung Lee; Byung Moo Yoo; Kwang Jae Lee; Sung Won Cho
Journal:  Hepatogastroenterology       Date:  2009 Sep-Oct

5.  Minimally invasive surgical enucleation or esophagogastrectomy for benign tumor of the esophagus.

Authors:  Ninh T Nguyen; Kevin M Reavis; Khaled El-Badawi; Marcelo W Hinojosa; Brian R Smith
Journal:  Surg Innov       Date:  2008-06       Impact factor: 2.058

6.  Classification of submucosal tumors in the gastrointestinal tract.

Authors:  Laura-Graves Ponsaing; Katalin Kiss; Mark-Berner Hansen
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

7.  Submucosal tunneling using endoscopic submucosal dissection for peritoneal access and closure in natural orifice transluminal endoscopic surgery: a porcine survival study.

Authors:  F Yoshizumi; K Yasuda; K Kawaguchi; K Suzuki; N Shiraishi; S Kitano
Journal:  Endoscopy       Date:  2009-08-10       Impact factor: 10.093

8.  Efficacy and safety of endoscopic submucosal dissection for tumors of the esophagogastric junction.

Authors:  N Kakushima; N Yahagi; M Fujishiro; S Kodashima; M Nakamura; M Omata
Journal:  Endoscopy       Date:  2006-02       Impact factor: 10.093

9.  Giant leiomyoma of the gastroesophageal junction: technique and results of endoscopic full-thickness resection.

Authors:  Davide Bona; Alberto Aiolfi; Stefano Siboni; Daniele Bernardi; Luigi Bonavina
Journal:  Clin Exp Gastroenterol       Date:  2011-11-30

10.  Endoscopic submucosal dissection as a treatment for gastric subepithelial tumors that originate from the muscularis propria layer: a preliminary analysis of appropriate indications.

Authors:  Seung Yeon Chun; Kyoung Oh Kim; Dong Seon Park; In Joung Lee; Ji Won Park; Sung-Hoon Moon; Il Hyun Baek; Jong Hyeok Kim; Choong Kee Park; Mi Jung Kwon
Journal:  Surg Endosc       Date:  2013-03-22       Impact factor: 4.584

View more
  4 in total

Review 1.  Endoscopic resection of esophageal and gastric submucosal tumors from the muscularis propria layer: submucosal tunneling endoscopic resection versus endoscopic submucosal excavation: A systematic review and meta-analysis.

Authors:  Fernando Lopes Ponte Neto; Diogo Turiani Hourneaux de Moura; Vitor Massaro Takamatsu Sagae; Igor Braga Ribeiro; Fabio Catache Mancini; Mateus Bond Boghossian; Thomas R McCarty; Nelson Tomio Miyajima; Edson Ide; Wanderley Marques Bernardo; Eduardo Guimarães Hourneaux de Moura
Journal:  Surg Endosc       Date:  2021-08-20       Impact factor: 4.584

2.  A Comparison of Endoscopic Closure and Laparoscopic Repair for Gastric Wall Defection.

Authors:  Qiao Qiao; Huiming Tu; Bojian Fei; Kebin Xu; Fan Yang; Jie Li; Qizhong Gao
Journal:  Gastroenterol Res Pract       Date:  2022-05-25       Impact factor: 1.919

3.  Predictors of difficult endoscopic resection of submucosal tumors originating from the muscularis propria layer at the esophagogastric junction.

Authors:  Yu-Ping Wang; Hong Xu; Jia-Xin Shen; Wen-Ming Liu; Yuan Chu; Ben-Song Duan; Jing-Jing Lian; Hai-Bin Zhang; Li Zhang; Mei-Dong Xu; Jia Cao
Journal:  World J Gastrointest Surg       Date:  2022-09-27

4.  Feasibility and Safety of Mark-Guided Submucosal Tunneling Endoscopic Resection for Treatment of Esophageal Submucosal Tumors Originating from the Muscularis Propria: A Single-Center Retrospective Study.

Authors:  Ben-Hua Wu; Rui-Yue Shi; Hai-Yang Zhang; Ting-Ting Liu; Yan-Hui Tian; Feng Xiong; Zheng-Lei Xu; Ding-Guo Zhang; De-Feng Li; Jun Yao; Li-Sheng Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.